Breast Cancer Research and Treatment

, Volume 134, Issue 2, pp 683–692

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

  • Lawrence J. Solin
  • Robert Gray
  • Lori J. Goldstein
  • Abram Recht
  • Frederick L. Baehner
  • Steven Shak
  • Sunil Badve
  • Edith A. Perez
  • Lawrence N. Shulman
  • Silvana Martino
  • Nancy E. Davidson
  • George W. SledgeJr.
  • Joseph A. Sparano
Clinical Trial
  • 459 Downloads

Abstract

The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local–regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1–3 positive lymph nodes or negative lymph nodes with tumor size >1.0 cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7 years (range = 3.7–11.6 years). The 10-year rates of local recurrence and local–regional recurrence were 5.4 % and 6.6 %, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local–regional recurrence on univariate or multivariate analyses (all P ≥ 0.12). The 10-year rates of local recurrence were 4.9 % for hormone receptor positive, HER2-negative tumors, 6.0 % for triple negative tumors, and 6.4 % for HER2-positive tumors (P = 0.76), and the 10-year rates of local–regional recurrence were 6.3, 6.9, and 7.2 %, respectively (P = 0.79). For hormone receptor-positive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1 % for low, intermediate, and high 21-gene recurrence score, respectively (P = 0.17), and the 10-year rates of local–regional recurrence were 3.8, 5.1, and 12.0 %, respectively (P = 0.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local–regional recurrence (hazard ratio 2.66; P = 0.03). The 10-year rates of local recurrence and local–regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.

Keywords

Early stage breast carcinoma Breast conservation treatment Radiation treatment 21-Gene recurrence score Local recurrence Local–regional recurrence 

References

  1. 1.
    Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683PubMedCrossRefGoogle Scholar
  2. 2.
    Kreike B, Halfwerk H, Armstrong N et al (2009) Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 15:4181–4190PubMedCrossRefGoogle Scholar
  3. 3.
    Nuyten DS, Kreike B, Hart AA et al (2006) Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62PubMedCrossRefGoogle Scholar
  4. 4.
    Voduc KD, Cheang M, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRefGoogle Scholar
  5. 5.
    Millar EK, Graham PH, O’Toole SA et al (2009) Prediction of local recurrence, distant metastasis, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701–4708PubMedCrossRefGoogle Scholar
  6. 6.
    Solin LJ, Hwang W-T, Vapiwala N (2009) Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer 9:96–100PubMedCrossRefGoogle Scholar
  7. 7.
    Freedman GM, Anderson PR, Li T et al (2009) Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 115:946–951PubMedCrossRefGoogle Scholar
  8. 8.
    Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRefGoogle Scholar
  9. 9.
    Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRefGoogle Scholar
  10. 10.
    Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378PubMedCrossRefGoogle Scholar
  11. 11.
    Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334PubMedCrossRefGoogle Scholar
  12. 12.
    Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRefGoogle Scholar
  13. 13.
    Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRefGoogle Scholar
  14. 14.
    Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581PubMedCrossRefGoogle Scholar
  15. 15.
    Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628–2634PubMedCrossRefGoogle Scholar
  16. 16.
    Abdulkarim BS, Cuartero J, Hanson J et al (2011) Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29:2852–2857PubMedCrossRefGoogle Scholar
  17. 17.
    Goldstein LJ, O’Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E2197. J Clin Oncol 26:4092–4099PubMedCrossRefGoogle Scholar
  18. 18.
    Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063–4071PubMedCrossRefGoogle Scholar
  19. 19.
    Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15:7693–7700PubMedCrossRefGoogle Scholar
  20. 20.
    Badve SS, Baehner FL, Gray RP et al (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473–2481PubMedCrossRefGoogle Scholar
  21. 21.
    Gray RJ (2009) Weighted analysis for cohort sampling designs. Lifetime Data Anal 15:24–40PubMedCrossRefGoogle Scholar
  22. 22.
    Ruan PK, Gray RJ (2008) Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 27:5709–5724PubMedCrossRefGoogle Scholar
  23. 23.
    Harris EE, Hwang W-T, Lee EA et al (2006) The impact of HER-2 status on local recurrence in women with stage I–II breast cancer treated with breast-conserving therapy. Breast J 12:431–436PubMedCrossRefGoogle Scholar
  24. 24.
    Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65PubMedCrossRefGoogle Scholar
  25. 25.
    Tang G, Shak S, Paik S et al (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP-B-14 and NSABP B-20. Breast Cancer Res Treat 127:133–142PubMedCrossRefGoogle Scholar
  26. 26.
    Cabioglu N, Hunt KK, Buchholz TA et al (2005) Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104:20–29PubMedCrossRefGoogle Scholar
  27. 27.
    Pass H, Vicini FA, Kestin LL et al (2004) Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Cancer 101:713–720PubMedCrossRefGoogle Scholar
  28. 28.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRefGoogle Scholar
  29. 29.
    Halyard MY, Dueck AC, Pisansky TM et al (2010) Impact of adjuvant trastuzumab on local regional recurrence: Data from the North Central Cancer Treatment Group (NCCTG) N9831 study (Abstract). Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, 8–12 December 2010Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Lawrence J. Solin
    • 1
  • Robert Gray
    • 2
    • 3
  • Lori J. Goldstein
    • 4
  • Abram Recht
    • 5
  • Frederick L. Baehner
    • 6
  • Steven Shak
    • 6
  • Sunil Badve
    • 7
  • Edith A. Perez
    • 8
  • Lawrence N. Shulman
    • 2
  • Silvana Martino
    • 9
  • Nancy E. Davidson
    • 10
  • George W. SledgeJr.
    • 11
  • Joseph A. Sparano
    • 12
  1. 1.Department of Radiation OncologyAlbert Einstein Medical CenterPhiladelphiaUSA
  2. 2.The Dana-Farber Cancer InstituteBostonUSA
  3. 3.Eastern Cooperative Oncology Group Coordinating CenterBostonUSA
  4. 4.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA
  5. 5.Department of Radiation OncologyBeth Israel Deaconess Medical CenterBostonUSA
  6. 6.Genomic Health, Inc.Redwood CityUSA
  7. 7.Department of PathologyIndiana UniversityIndianapolisUSA
  8. 8.Mayo ClinicJacksonvilleUSA
  9. 9.The Angeles Clinic and Research InstituteSanta MonicaUSA
  10. 10.University of Pittsburgh Cancer InstitutePittsburghUSA
  11. 11.Department of Medical OncologyIndiana UniversityIndianapolisUSA
  12. 12.Department of Medical Oncology, Montefiore Medical CenterAlbert Einstein College of MedicineNew YorkUSA

Personalised recommendations